Table of Contents
Executive Summary — 5
Croatia Pharmaceuticals Industry
SWOT — 6
Croatia Political SWOT — 7
Croatia Economic SWOT — 7
Croatia Business Environment
SWOT — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Regional Pharma Business Environment
Ratings — 9
Limits Of Potential
Returns — 10
Risks To Realisation Of
Returns — 11
Croatia – Market
Summary — 12
Regulatory Regime — 14
Intellectual Property Regime — 15
Pricing
Regime — 16
Reimbursement Regime — 17
Recent Pricing And Reimbursement Developments — 19
OTC
Regulations — 19
Industry Trends And
Developments — 21
Epidemiology — 21
Table: Disease Burden In CEE — 22
Healthcare
Provision — 23
Healthcare
Expenditure — 23
Healthcare Debts — 24
Healthcare Reform — 25
Domestic Pharmaceutical
Industry — 27
Domestic Company
Activity — 28
Foreign Company
Activity — 29
Table: Lukaps’ Time
Line — 30
Pharmaceutical Retail — 30
Research And Development Sector — 32
Clinical
Trials — 33
Medical Devices — 34
Industry Forecast Scenario — 35
Overall Market
Forecast — 35
Table: Croatia – Drug Expenditure
Indicators, Historical Data and Forecasts — 36
Key Growth
Factors – Industry — 37
Table: Croatia –
Health Expenditure Indicators, Historical Data and
Forecasts — 38
Key Growth Factors –
Macroeconomic — 39
Table: Croatia - Economic Activity,
2005-2013 — 40
Prescription Market
Forecast — 41
Table: Croatia – Prescription Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 42
Patented Market
Forecast — 44
Table: Croatia – Patented Market
Indicators, Historical Data and Forecasts — 45
Generics
Market Forecast — 46
Table: Croatia – Generics
Market Indicators, Historical Data and Forecasts — 46
OTC
Market Forecast — 47
Table: Croatia – OTC Market
Indicators, Historical Data and Forecasts (US$mn unless otherwise
stated) — 48
Export/Import
Forecasts — 49
Table: Croatia – Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 49
Other Healthcare Forecasts — 50
Table: Croatia –
Other Healthcare Indicators, Historical Data and
Forecasts — 50
Key Risks To BMI’s Forecast
Scenario — 51
Competitive
Landscape — 52
Company Monitor — 53
International Company Profiles — 53
GlaxoSmithKline — 53
Pfizer — 54
Sanofi-Aventis — 55
Novartis — 56
Merck & Co — 57
Krka — 58
Indigenous
Company Profiles — 59
Pliva — 59
Belupo — 62
Country Snapshot: Croatia Demographic
Data — 65
Section 1: Population — 65
Table: Demographic Indicators, 2005-2030 — 65
Table:
Rural/Urban Breakdown, 2005-2030 — 66
Section 2: Education
And Healthcare — 66
Table: Education,
2000-2003 — 66
Table: Vital Statistics,
2005-2030 — 66
Section 3: Labour Market And Spending
Power — 67
Table: Employment Indicators,
1999-2004 — 67
Table: Consumer Expenditure, 2000-2010
(US$) — 68
Table: Average Annual Wages,
2000-2010 — 68
BMI Forecast
Modelling — 69
How We Generate Our Pharmaceutical Industry
Forecasts — 69
Pharmaceutical Business Environment Ratings
Methodology — 70
Ratings Overview — 70
Table: Pharmaceutical Business Environment Indicators — 71
Weighting — 72
Table: Weighting Of
Components — 72
Sources — 72
| 
View Cart
